INTRODUCTION: Two 7-fluoroimidazobenzodiazepines (AH114726 and GEH120348), analogs of flumazenil, were labeled with fluorine-18 and evaluated as alternative radioligands for in vivo imaging of the GABAA/benzodiazepine receptor by comparing them to [(11)C]flumazenil in rhesus monkey. METHODS: Radiotracers were prepared from the corresponding nitro-precursors in an automated synthesis module, and primate imaging studies were conducted on a Concorde MicroPET P4 scanner. The brain was imaged for 60 (12 × 5 min frames) or 90 min (18 × 5 min frames), and data was reconstructed using the 3D MAP algorithm. Specificity of [(18)F]AH114726 and [(18)F]GEH120348 was confirmed by displacement studies using unlabeled flumazenil. RESULTS: [(18)F]GEH120348 and [(18)F]AH114726 were obtained in 13-24% yields (end of synthesis) with high chemical (>95%) and radiochemical (>99%) purities, and high specific activities (2061 ± 985 Ci/mmol). The in vivo pharmacokinetics of [(18)F]AH114726 and [(18)F]GEH120348 were determined in a non-human primate and directly compared with [(11)C]flumazenil. Both fluorine-18 radioligands showed time-dependent regional brain distributions that correlated with the distribution of [(11)C]flumazenil and the known concentrations of GABAA/benzodiazepine receptors in the monkey brain. [(18)F]AH114726 exhibited maximal brain uptake and tissue time-radioactivity curves that were most similar to [(11)C]flumazenil. In contrast, [(18)F]GEH120348 showed higher initial brain uptake but very different pharmacokinetics with continued accumulation of radioactivity into the cortical regions of high GABA/benzodiazepine receptor concentrations and very little clearance from the regions of low receptor densities. Rapid washout of both radiotracers occurred upon treatment with unlabeled flumazenil. CONCLUSION: The ease of the radiochemical synthesis, together with in vivo brain pharmacokinetics most similar to [(11)C]flumazenil, support that [(18)F]AH114726 is a suitable option for imaging the GABAA receptor.
INTRODUCTION: Two 7-fluoroimidazobenzodiazepines (AH114726 and GEH120348), analogs of flumazenil, were labeled with fluorine-18 and evaluated as alternative radioligands for in vivo imaging of the GABAA/benzodiazepine receptor by comparing them to [(11)C]flumazenil in rhesus monkey. METHODS: Radiotracers were prepared from the corresponding nitro-precursors in an automated synthesis module, and primate imaging studies were conducted on a Concorde MicroPET P4 scanner. The brain was imaged for 60 (12 × 5 min frames) or 90 min (18 × 5 min frames), and data was reconstructed using the 3D MAP algorithm. Specificity of [(18)F]AH114726 and [(18)F]GEH120348 was confirmed by displacement studies using unlabeled flumazenil. RESULTS: [(18)F]GEH120348 and [(18)F]AH114726 were obtained in 13-24% yields (end of synthesis) with high chemical (>95%) and radiochemical (>99%) purities, and high specific activities (2061 ± 985 Ci/mmol). The in vivo pharmacokinetics of [(18)F]AH114726 and [(18)F]GEH120348 were determined in a non-human primate and directly compared with [(11)C]flumazenil. Both fluorine-18 radioligands showed time-dependent regional brain distributions that correlated with the distribution of [(11)C]flumazenil and the known concentrations of GABAA/benzodiazepine receptors in the monkey brain. [(18)F]AH114726 exhibited maximal brain uptake and tissue time-radioactivity curves that were most similar to [(11)C]flumazenil. In contrast, [(18)F]GEH120348 showed higher initial brain uptake but very different pharmacokinetics with continued accumulation of radioactivity into the cortical regions of high GABA/benzodiazepine receptor concentrations and very little clearance from the regions of low receptor densities. Rapid washout of both radiotracers occurred upon treatment with unlabeled flumazenil. CONCLUSION: The ease of the radiochemical synthesis, together with in vivo brain pharmacokinetics most similar to [(11)C]flumazenil, support that [(18)F]AH114726 is a suitable option for imaging the GABAA receptor.
Authors: Nikolaj N Ryzhikov; Nicholas Seneca; Raisa N Krasikova; Natalia A Gomzina; Evgeny Shchukin; Olga S Fedorova; Dmitrij A Vassiliev; Balázs Gulyás; Håkan Hall; Ivanka Savic; Christer Halldin Journal: Nucl Med Biol Date: 2005-02 Impact factor: 2.408
Authors: G Gründer; T Siessmeier; C Lange-Asschenfeldt; I Vernaleken; H G Buchholz; P Stoeter; A Drzezga; H Lüddens; F Rösch; P Bartenstein Journal: Eur J Nucl Med Date: 2001-10
Authors: Ikuo Odano; Christer Halldin; Per Karlsson; Andrea Varrone; Anu J Airaksinen; Raisa N Krasikova; Lars Farde Journal: Neuroimage Date: 2008-12-24 Impact factor: 6.556
Authors: V W Pike; C Halldin; C Crouzel; L Barré; D J Nutt; S Osman; F Shah; D R Turton; S L Waters Journal: Nucl Med Biol Date: 1993-05 Impact factor: 2.408
Authors: Alexander Jackson; Benedicte B Guilbert; Stuart D Plant; Julian Goggi; Mark R Battle; John L Woodcraft; Alessandra Gaeta; Clare L Jones; Denis R Bouvet; Paul A Jones; Dennis M O'Shea; Penny Hao Zheng; Samantha L Brown; Amanda L Ewan; William Trigg Journal: Bioorg Med Chem Lett Date: 2012-11-28 Impact factor: 2.823
Authors: Gassan Massaweh; Esther Schirrmacher; Christian la Fougere; Miriam Kovacevic; Carmen Wängler; Dean Jolly; Paul Gravel; Andrew J Reader; Alexander Thiel; Ralf Schirrmacher Journal: Nucl Med Biol Date: 2009-07-29 Impact factor: 2.408
Authors: M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488